ADH1A and neoplasm: The N-cadherin antagonist ADH-1 has been shown to be an anti-angiogenic agent, and several clinic trials have revealed that it can be used as an antitumor drug.23–25 According to a recent paper, N-cadherin regulates the EMT process in advanced cancers.19 Additionally, immunosuppression is linked to EMT.27–31 As previously reported, EMT enforces immunosuppression and helps cancer cells escape immunosurveillance, which is known to play a major role in tumor invasion.14–18 Therefore, we propose that N-cadherin mediates immunosuppression through the initiation of the EMT.